Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Price:
12.87 USD
-5.44%
Updated:
May 10, 2024
Y-mAbs Therapeutics Inc
EPS (Diluted)
|
Y-mAbs Therapeutics Inc
EPS (Diluted) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
EPS (Diluted)
$0
|
CAGR 3-Years
45%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
0%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
18%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$13
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$33
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Y-mAbs Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-0.5
USD
-0.5
USD
Based on the financial report for Dec 31, 2023, Y-mAbs Therapeutics Inc's EPS (Diluted) amounts to -0.5 USD.
What is Y-mAbs Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
20%
20%
Over the last year, the EPS (Diluted) growth was 78%. The average annual EPS (Diluted) growth rates for Y-mAbs Therapeutics Inc have been 45% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
